Ru-Chen Xu

机构：Fudan University, Zhongshan Hospital

发表论文 14 篇 · 总被引 283 次 · h-index 8

代表论文

• Disruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma (2023 · Gastroenterology · 被引 117)
• Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages (2021 · Journal of Translational Medicine · 被引 59)
• Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma (2022 · ACS Applied Materials & Interfaces · 被引 23)
• Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma (2024 · International Journal of Biological Sciences · 被引 18)
• Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway (2023 · Hepatology International · 被引 15)
• Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma (2022 · Nanomaterials · 被引 15)